What is it about?
safinamide is a drug with a double mechanism of action, dopaminergic and non-dopaminergic. Safinamide modulates the release of glutamate, and glutamate is believed to be involved in dyskinesia, chronic pain and mood disorders in Parkinson's Disease patients. With this analysis safinamide has shonw to be effective in mitigate the neuropathic pain of PD patients, and reduce the concomitant use of analgesics of about 24%.
Featured Image
Why is it important?
Up to 80% of Parkinsonian patients suffer for chronic pain and at there are no drugs for this comorbidity. Patients use several pain killer drugs, such as analgesics, antinflammatories and opiodis, with several adverse events.
Perspectives
These data, even if preliminary, are important to give an idea of the potential benefits of safinamide in PD non-motor symptoms.
Dr Carlo Cattaneo
Zambon SpA
Read the Original
This page is a summary of: Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis, Journal of Parkinson s Disease, February 2017, IOS Press,
DOI: 10.3233/jpd-160911.
You can read the full text:
Contributors
The following have contributed to this page
